X
Xenon Pharmaceuticals Inc. (XENE)
NGM – Real Time Price. Currency in USD
52.91
-0.29 (-0.55%)
At close: Jun 18, 2026, 4:00 PM EDT
52.92
+0.01 (0.02%)
After-hours: Jun 18, 2026, 6:35 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
52.91
-0.29 (-0.55%)
At close: Jun 18, 2026, 4:00 PM EDT
52.92
+0.01 (0.02%)
After-hours: Jun 18, 2026, 6:35 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 27.79 | 6.05 | 10 | |
| Quick ratio | 27.79 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 9M | N/A | N/A | 8M | N/A |
| Gross Profit | N/A | -4M | -3M | 5M | -2M |
| Operating Income | -129M | -214M | -279M | -373M | -413M |
| Net Income | -125M | -182M | -234M | -346M | -383M |
| EBITDA | -128M | -211M | -277M | -371M | -410M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -7.11 | 1.0 |
| Next quarter | N/A | -3 | 1.0 |
| Current year | -70.74 | -9.61 | 1.0 |
| Next year | 1609.38 | -3.23 | 5.5 |
| Weighted average score | 2.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 2.81 | 10.69 | -12.2 | 5.5 |
| Y/Y | -99.99 | -57.26 | -40.95 | -44.3 | 1.0 |
| 3y average | 632.67 | -40.51 | -29.19 | -40.96 | 3.3 |
| 5y average | 361.3 | -70.79 | -44.49 | -41.08 | 3.3 |
| Weighted average score | 3.3 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $545.9M significantly exceed its total debt $7.5M, ensuring strong financial flexibility
Total current assets $1.1B exceed Total current liabilities $39.8M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$89.0M limits the company's ability to reinvest or pay down debt